Evaluating biosimilars requires payers to go beyond cost considerations: safety and efficacy, reliability of supply and logistics, and the impact of state laws on substitution and interchangeability must all be deliberated.
Keywords: Biosimilars; affordability and access; benefit management; managed care; payers; pharmacoeconomics.